首页> 外文学位 >Characterization of polyacrylamide nanoparticles for biomedical applications: Toxicology, pharmacology, and therapy.
【24h】

Characterization of polyacrylamide nanoparticles for biomedical applications: Toxicology, pharmacology, and therapy.

机译:用于生物医学的聚丙烯酰胺纳米颗粒的表征:毒理学,药理学和疗法。

获取原文
获取原文并翻译 | 示例

摘要

Polyacrylamide (PAA) nanoparticles have been developed for real-time intracellular measurements with applications for analysis of drug, toxin, and environmental effects on cell function. Chemically, the flexibility and ease of synthesis of PAA nanoparticles has also led to their development for imaging tumors and the simultaneous in situ treatment of cancer. The matrices are composed of cross-linked polyacrylamide. Due to their novelty, the toxicology, pharmacology, and therapeutic potential have not been defined. Therefore, this thesis tests the toxicology (biocompatibility) and pharmacology (pharmacokinetics, tissue distribution, and excretion), of the polyacrylamide matrix after intravenous administration into a rodent model. In addition, this thesis tests the utility of the polyacrylamide nanoparticle in photodynamic therapy (PDT) for treating cancer. Data acquired in this thesis provide evidence that nanoparticles comprised of polyacrylamide are non-toxic after i.v. administration. Pharmacokinetic results indicate that the reticular endothelial system is responsible for removing a significant percentage of the administered dose. The stability of the matrix indicated prolonged degradation and as a result modest recovery in the excrement. In addition, because the matrix is a polymer (foreign body) and exhibits long-term exposure to the R.E.S, immunologic responses associated with inflammation and recruitment of antigen presenting cells (APC) were measured. Results from these data do not implicate the polymer, after sequestration into the RES, with inflammatory signaling or trafficking of dendritic cells to the liver or spleen. Additional experiments provide evidence of hepatic sinusoidal-lymph translocation of a percentage of the administered dose to the portal lymph node.; Development of these nanoparticles for PDT proved successful at the in vitro level. Results indicate that polyacrylamide nanoparticles, carrying a photosensitive dye are capable of producing sufficient amounts of singlet oxygen and inducing cell death in a resistant cell model for brain cancer.; These data provided in this dissertation characterize polyacrylamide nanoparticles for future development as a device in various biomedical applications. The polymer matrix is biocompatible, non-immunogenic and therapeutically attuned for utilization in PDT.
机译:聚丙烯酰胺(PAA)纳米粒子已开发用于实时细胞内测量,并用于分析药物,毒素和环境对细胞功能的影响。化学上,PAA纳米颗粒合成的灵活性和易用性也导致了它们在成像肿瘤和同时进行原位癌症治疗方面的发展。基质由交联的聚丙烯酰胺组成。由于它们的新颖性,尚未定义毒理学,药理学和治疗潜力。因此,本论文测试了在啮齿动物模型中静脉内给药后聚丙烯酰胺基质的毒理学(生物相容性)和药理学(药代动力学,组织分布和排泄)。另外,本论文测试了聚丙烯酰胺纳米颗粒在光动力疗法(PDT)治疗癌症中的实用性。本论文中获得的数据提供了证据,证明由聚丙烯酰胺组成的纳米粒子在静脉内注射后无毒。管理。药代动力学结果表明,网状内皮系统负责去除相当大比例的给药剂量。基质的稳定性表明降解时间延长,结果排泄物适度恢复。此外,由于基质是聚合物(异物)并且长期暴露于R.E.S,因此测量了与炎症和抗原呈递细胞(APC)募集相关的免疫反应。这些数据的结果表明,在螯合入RES后,该聚合物并未暗示炎症信号或树突状细胞向肝或脾的运输。其他实验提供了肝正弦淋巴转移至门淋巴结的一定剂量剂量的证据。这些用于PDT的纳米颗粒的开发在体外水平上被证明是成功的。结果表明,带有光敏染料的聚丙烯酰胺纳米粒子能够产生足够量的单线态氧,并在脑癌耐药细胞模型中诱导细胞死亡。本论文提供的这些数据表征了聚丙烯酰胺纳米颗粒作为未来在各种生物医学应用中的一种装置。聚合物基质具有生物相容性,非免疫原性,并且经过治疗调整可用于PDT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号